The company approved a share buyback plan on April 22, 2026, with a total funding of no less than RMB 250 million and no more than RMB 300 million. The buyback will utilize self-owned funds or special loans and is intended for equity incentive plans and/or employee stock ownership plans. The first buyback occurred on April 29, 2026, with 602,700 shares repurchased at prices between RMB 18.57 and RMB 18.96 per share.
Summary generated by AI · Always verify with source document
Securities Code: 300109
Securities Abbreviation: Xinkaiyuan
Announcement Number: 2026-045
Baoyao Xinkaiyuan Medical Technology Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.